Want to see IN:GLAXO full AI Analyst Report?
Top Page
GlaxoSmithKline Pharmaceuticals Limited
(GLAXO)
Select Model
Select Model
Rating:69Neutral
Price Target:
₹2,326.00
▼(-6.34% Downside)
Action:Reiterated
Date:05/15/26
The score is led by strong financial performance—improving margins, high ROE, and minimal leverage—partly offset by a neutral-to-weak technical backdrop (below longer-term moving averages) and a relatively expensive valuation (high P/E despite a moderate dividend yield).
Positive Factors
Improving Profitability
Sustained margin improvement to ~27% net and ~33% EBIT indicates stronger operating leverage and/or a higher-margin product mix. Durable higher margins enhance cash generation, support reinvestment in brands and R&D, and improve return on equity over the medium term.
Negative Factors
Profitability Volatility
Historical swings, including a non-recurring >50% net margin in 2022, make baseline margin assumptions less reliable. This volatility complicates multi-quarter forecasting, can mask structural margin trends, and raises the risk that future profits could lapse if transient gains reverse.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving Profitability
Sustained margin improvement to ~27% net and ~33% EBIT indicates stronger operating leverage and/or a higher-margin product mix. Durable higher margins enhance cash generation, support reinvestment in brands and R&D, and improve return on equity over the medium term.
Read all positive factors
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹424.65B
Dividend Yield2.16%
Average Volume (3M)1.83K
Price to Earnings (P/E)40.1
Beta (1Y)0.71
Revenue Growth1.93%
EPS Growth11.69%
CountryIN
Employees3,103
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)61.15
Shares Outstanding169,406,040
10 Day Avg. Volume1,472
30 Day Avg. Volume1,831
Financial Highlights & Ratios
PEG Ratio3.20
Price to Book (P/B)17.06
Price to Sales (P/S)10.12
P/FCF Ratio39.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)69.53
Revenue Forecast (FY)₹42.07B
GlaxoSmithKline Pharmaceuticals Limited Business Overview & Revenue Model
Company Description
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescriptio...
How the Company Makes Money
GLAXO primarily makes money by selling pharmaceutical and healthcare products in India through a branded, formulation-led model. Revenue is mainly generated from: (1) Domestic sales of branded prescription medicines: The company markets finished-d...
GlaxoSmithKline Pharmaceuticals Limited Financial Statement Overview
Summary
Income Statement
82
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
78
Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 38.22B | 37.26B | 34.42B | 32.26B | 32.64B |
| Gross Profit | 16.65B | 22.53B | 20.22B | 18.68B | 18.14B |
| EBITDA | 14.75B | 13.28B | 8.88B | 9.04B | 8.49B |
| Net Income | 10.36B | 9.28B | 5.90B | 6.11B | 16.95B |
Balance Sheet | |||||
| Total Assets | 43.24B | 41.08B | 35.57B | 33.27B | 46.33B |
| Cash, Cash Equivalents and Short-Term Investments | 27.56B | 24.98B | 18.57B | 16.54B | 29.03B |
| Total Debt | 332.70M | 99.50M | 186.65M | 155.40M | 200.76M |
| Total Liabilities | 20.56B | 21.57B | 17.79B | 15.85B | 19.70B |
| Stockholders Equity | 22.67B | 19.51B | 17.78B | 17.41B | 26.63B |
Cash Flow | |||||
| Free Cash Flow | 9.67B | 12.67B | 5.51B | 4.40B | 7.76B |
| Operating Cash Flow | 10.22B | 12.90B | 5.82B | 4.84B | 8.11B |
| Investing Cash Flow | 2.78B | -458.10M | 87.12M | 8.08B | -4.06B |
| Financing Cash Flow | -7.37B | -7.69B | -5.61B | -15.43B | -5.24B |
GlaxoSmithKline Pharmaceuticals Limited Technical Analysis
Positive
2483.35
Price Trends
2315.28
Positive
2347.94
Positive
2419.49
Positive
Market Momentum
52.89
Negative
69.21
Neutral
74.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAXO, the sentiment is Positive. The current price of 2483.35 is above the 20-day moving average (MA) of 2405.97, above the 50-day MA of 2315.28, and above the 200-day MA of 2419.49, indicating a bullish trend. The MACD of 52.89 indicates Negative momentum. The RSI at 69.21 is Neutral, neither overbought nor oversold. The STOCH value of 74.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:GLAXO.
GlaxoSmithKline Pharmaceuticals Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹592.45B | 38.41 | ― | 1.68% | 8.11% | 9.73% | |
71 Outperform | ₹417.84B | 39.27 | ― | 1.07% | 14.50% | 47.08% | |
69 Neutral | ₹424.65B | 40.14 | ― | 2.16% | 1.93% | 11.69% | |
69 Neutral | ₹1.15T | 29.53 | ― | 0.87% | 2.23% | -26.44% | |
64 Neutral | ₹214.67B | 28.92 | ― | 0.69% | 10.45% | -5.88% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
IN:GLAXO
GlaxoSmithKline Pharmaceuticals Limited
2,455.05
-611.51
-19.94%
IN:ABBOTINDIA
Abbott India Limited
28,013.60
-5,666.92
-16.83%
IN:CIPLA
Cipla Ltd
1,418.40
-49.87
-3.40%
IN:GLAND
Gland Pharma Ltd.
2,449.75
467.42
23.58%
IN:PFIZER
PFIZER LIMITED
4,568.40
-662.53
-12.67%
IN:SANOFICONR
Sanofi Consumer Healthcare India Limited
4,576.10
-435.27
-8.69%
GlaxoSmithKline Pharmaceuticals Limited Corporate Events
GSK Pharma India Shareholders Approve Appointment of CFO Ronojit Biswas via Postal Ballot
Apr 8, 2026
GlaxoSmithKline Pharmaceuticals Limited has concluded a postal ballot process conducted via remote e-voting to seek shareholder approval for key board and management changes. The process, held in compliance with the Companies Act and SEBI listing ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.